GlassScriptPhysician profile
Scott Gaspard
NPI 1619147071
$1,565.25
in general payments reported to CMS, 2019-2025
12 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2021: $118 · 2022: $176 · 2023: $81.43 · 2024: $646 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $433.48 | 2023-2025 | |
| Revance Therapeutics, INC. | $336.21 | 2024-2025 | Daxxify |
| Allergan, INC. | $152.75 | 2022 | |
| Galderma Laboratories, L.P. | $144.56 | 2025 | |
| Tela Bio, INC. | $133.11 | 2019 | |
| Ethicon US, LLC | $118.32 | 2021 | |
| Lilly USA, LLC | $67.69 | 2024-2025 | Zepbound, Olumiant, Taltz |
| Incyte Corporation | $53.39 | 2024-2025 | Opzelura |
| Biofrontera INC. | $39.05 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $35.00 | 2025 | Bimzelx |
| Vertex Pharmaceuticals Incorporated | $29.10 | 2025 | |
| Leo Pharma INC. | $22.59 | 2025 | Anzupgo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Gaspard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.